Company Overview and News

5
Canada pension plan offers country’s largest green bond

2018-06-13 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
MFC.PR.B MFC.PR.F MFC.PR.C MFC 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
AltaGas sells 35% of B.C. hydroelectric operation for $922 million

2018-06-13 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
UPDATE 1-AltaGas sells 35 pct stake in hydro projects for C$922 mln

2018-06-13 reuters
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in three hydroelectric projects in Northwest British Columbia for C$922 million ($707.87 million) to help fund its acquisition of U.S.-based WGL Holdings Inc.
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ALA.PR.G ATGFF 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
AltaGas sells 35 pct stake in hydro projects for C$922 mln

2018-06-13 reuters
June 13 (Reuters) - Canadian utility AltaGas Ltd said on Wednesday it would sell a 35 percent stake in the Northwest British Columbia Hydro Electric Facilities for C$922 million ($707.87 million).
MFC.PR.B MFC.PR.F ALA.PR.U MFC.PR.C WGL ALA.PR.B ALA.PR.A ALA.PR.I MFC ATGFF ALA.PR.G 0945 ALA.PR.E MFC.PR.I MFC.PR.J MFC MFC.PR.H ALA MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
Elliott, Mulroney expected to snag key cabinet posts in Ford government

2018-06-10 cbc.ca
When Doug Ford unveils his Ontario provincial government cabinet, it's expected to be much smaller than the current team assembled by Kathleen Wynne.
MFC.PR.B MFC.PR.F MFC.PR.C MFC 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

13
Demand for green bonds set to soar in Asia

2018-06-09 business.inquirer.net
Mr Vivek Pathak, IFC’s director for East Asia and the Pacific, and Mr Ng Yao Loong, MAS’ assistant managing director, development and international group, at the signing of a memorandum of understanding, which will see both parties working together to spur green bond issuances by financiers in Asia.PHOTO: MAS
MFC.PR.B IFK IFX MFC.PR.F SPXCF MFC.PR.C S68 MFC SPXCY 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

19
Why Is Manulife (MFC) Up 4% Since Its Last Earnings Report?

2018-06-01 zacks
A month has gone by since the last earnings report for Manulife Financial Corp (MFC - Free Report) . Shares have added about 4% in that time frame.
MFC.PR.B FISI MFC.PR.F MFC.PR.C OCN FIISO FIISP MFC 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
M Split Corp.: Monthly Dividend Declared for Class I Preferred Shares

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- M Split Corp. ("M Split") declares its monthly distribution of $0.03125 per share ($0.375 annually) for Class I Preferred shareholders. The Class I Preferred share dividends are paid at an annual rate of 7.50% based on the $5 notional issue price. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018. M Split invests in common shares of Manulife Financial Corporation, the largest life insurer in Canada offering financial products and wealth management services.
MFC.PR.B MFC.PR.F MFC.PR.C MFC 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

182
North American Financial 15 Split Corp. Regular Monthly Dividend Declaration for Class A & Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- North American Financial 15 Split Corp. (The "Company") declares its regular monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04583 for each Preferred share ($0.550 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B C.WSA MFC.PR.F MFC.PR.C GS.PRB GS.PRA CIFAF GLSSP GWO JBK TFG GS.PRJ GS.PRI MFC 0945 GS.PRD CGBBW GS.PRC CIX SLFYF GS.PRN GWLIF SLF GS.PRK WFCNP FFN NAF.UN SLF WFC.PRL WFC.PRJ TD WFC.PRT GS C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP SLF.PR.G C.PRU WFC.PRY WFC.PRX TD SLF.PR.B WFC.PRW SLF.PR.E WFC.PRV C.PRS SLF.PR.D WFC WFC.WS TNTTF C.PRL C GSC GS.PRICL C.PRJ C.PRK C.PRG GSJ C.PRC SLF GWLOF C.PRPCL MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H GJS MFC.PR.M GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L

37
Dividend 15 Split Corp. Declares 170th Consecutive Monthly Distribution

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. declares its 170th consecutive monthly distribution of $0.10000 for each Class A share ($1.20 annually) and $0.04375 for each Preferred share ($0.525 annually). Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF TD BCE SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TRP TNTTF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF

32
Dividend 15 Split Corp. II Regular Monthly Dividend Declaration for Preferred Share

2018-05-18 globenewswire
TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Dividend 15 Split Corp. II ("Dividend 15 II") declares its regular monthly distribution of $0.04375 for each Preferred share. Distributions are payable June 8, 2018 to shareholders on record as at May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TAC CIFAF BCE SLF.PR.G SLF.PR.B SLF.PR.E SLF.PR.D TRP DF SLF MFC 0945 MFC.PR.I CIX TRI MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M MFC.PR.N MFC.PR.K TU MFC.PR.L SLF

15
Manulife Financial - Overvalued Now, But Still An Opportunity For Growth

2018-05-16 seekingalpha
Most of Manulife's growth has come from their Asia/Pacific segment. This segment will continue to be one of their major focuses going forward.
MFC.PR.B SLF MFC.PR.F MFC.PR.C SLF MFC 0945 VALU MFC.PR.I SLF.PR.G MFC.PR.J MFC MFC.PR.H SLFYF MFC.PR.M SLF.PR.B MFC.PR.N SLF.PR.E MFC.PR.K SLF.PR.D MFC.PR.L SLF

19
Big 8 Split Inc. Announces Quarterly Dividends on Class D Preferred Shares and Class D Capital Shares

2018-05-11 globenewswire
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- Big 8 Split Inc. (TSX:BIG.D) (TSX:BIG.pr.D) (the “Company”) announced today that it has declared a quarterly dividend of $0.1125 per Class D Preferred Share. In addition, a quarterly dividend on its Class D Capital Shares was declared of $0.043 per Class D Capital Share. The dividends on both the Class D Preferred Shares and Class D Capital Shares are payable on June 15, 2018 to holders of record on May 31, 2018.
MFC.PR.B SLF MFC.PR.F MFC.PR.C TD GWO SLF.PR.G SLF.PR.B TD SLF.PR.E SLF.PR.D TNTTF SLF MFC 0945 GWLOF MFC.PR.I MFC.PR.J GWO.PR.I MFC GWO.PR.H MFC.PR.H SLFYF MFC.PR.M GWLIF GWO.PR.F MFC.PR.N MFC.PR.K MFC.PR.L SLF

8
Insurers lead Hong Kong stocks higher in morning session

2018-05-08 scmp
Hong Kong stocks began the morning session higher on Tuesday, driven by gains in insurers and overnight advances in Wall Street as investors await a decision by the US to reimpose sanctions on Iran.
MFC.PR.B MFC.PR.F MFC.PR.C GELYF GELYY 0175 MFC 2628 0945 0700 MFC.PR.I MFC.PR.J MFC LFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

5
BRIEF-Manulife Announces Subordinated Green Bond Issue

2018-05-07 reuters
* MANULIFE FINANCIAL CORP - INTENDS TO ISSUE $600 MILLION PRINCIPAL AMOUNT OF 3.317% FIXED/FLOATING SUBORDINATED DEBENTURES DUE MAY 9, 2028
MFC.PR.B MFC.PR.F MFC.PR.C MFC 0945 MFC.PR.I MFC.PR.J MFC MFC.PR.H MFC.PR.M MFC.PR.N MFC.PR.K MFC.PR.L

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...